Stem Cell Transplant

Post-remission therapy with allogeneic hematopoietic-cell transplant (alloHSCT) is a potentially curative therapy for eligible patients that consists of pretransplant cytoreductive conditioning and an immunologic graft-versus-leukemia effect that occurs when the donor’s immune cells attack the transplant recipient’s leukemia.

  • AlloHSCT is often given to patients with higher-risk disease who likely would not respond as well to other traditional approaches1

Allogeneic transplant is potentially curative for eligible patients with AML in first CR. 50%-60% of patients with AML with intermediate or high-risk cytogenetics achieve cure following first CR.2

Significant comorbidities can prevent patients from being eligible for allogeneic transplant, and treatment must be planned accordingly for these patients.2

References: 1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152. 2. Saultz JN, Garzon R. Acute myeloid leukemia: a concise review. J Clin Med. 2016;5(3):33.